To assess treatment decision and outcome in patients referred for Transcatheter Aortic Valve Implantation (TAVI) in addition to predictive factors of mortality after TAVI. Methods: Three-centre prospective observational study including 358 patients. Endpoints were defined according to the Valve Academic Research Consortium. Results: Of the 358 patients referred for TAVI, TAVI was performed in 235 patients (65%), surgical aortic valve replacement (AVR) in 24 (7%) and Medical Therapy (MT) in 99 (28%). Reasons to decline TAVI in favour of AVR/MT were patient's preference (29%) and peripheral vascular disease (15%; Figure 1 ). The logistic EuroSCORE was significantly higher in patients who underwent TAVI and MT in comparison to those undergoing AVR (19 vs. 10%, pϭ0.007). At 30 days, all-cause mortality and the combined safety endpoint was, respectively, 9 and 24% after TAVI and 8 and 25% after AVR. All-cause mortality was significantly lower in the TAVI group compared to the MT group at 6 months, 1 year and 2 years (12% vs. 22%, 21% vs. 33% and 31% vs. 55%, respectively, pϽ0.001). Multivariable analysis revealed that blood transfusion (HR: 1.19; 95% CI: 1.05-1.33), pre-existing renal failure (HR: 1.18; 95% CI: 1.06-1.33) and STS score (HR: 1.06; 95% CI: 1.02-1.10) were independent predictors of mortality at a median of 10 (IQR: 3-23) months after TAVI.
Background:
To assess treatment decision and outcome in patients referred for Transcatheter Aortic Valve Implantation (TAVI) in addition to predictive factors of mortality after TAVI. Methods: Three-centre prospective observational study including 358 patients. Endpoints were defined according to the Valve Academic Research Consortium. Results: Of the 358 patients referred for TAVI, TAVI was performed in 235 patients (65%), surgical aortic valve replacement (AVR) in 24 (7%) and Medical Therapy (MT) in 99 (28%). Reasons to decline TAVI in favour of AVR/MT were patient's preference (29%) and peripheral vascular disease (15%; Figure 1 ). The logistic EuroSCORE was significantly higher in patients who underwent TAVI and MT in comparison to those undergoing AVR (19 vs. 10%, pϭ0.007). At 30 days, all-cause mortality and the combined safety endpoint was, respectively, 9 and 24% after TAVI and 8 and 25% after AVR. All-cause mortality was significantly lower in the TAVI group compared to the MT group at 6 months, 1 year and 2 years (12% vs. 22%, 21% vs. 33% and 31% vs. 55%, respectively, pϽ0.001). Multivariable analysis revealed that blood transfusion (HR: 1.19; 95% CI: 1.05-1.33), pre-existing renal failure (HR: 1.18; 95% CI: 1.06-1.33) and STS score (HR: 1.06; 95% CI: 1.02-1.10) were independent predictors of mortality at a median of 10 (IQR: 3-23) months after TAVI.
Conclusions:
Approximately two-thirds of the patients referred for TAVI receive this treatment with gratifying short-and long-term survival. Another 7% underwent AVR. Prognosis is poor in patients who do not receive valve replacement therapy. Background: Aortic stenosis is the most common valvulopathy in industrialized countries which is treated with trancatheter aortic valve implantation (TAVI) when patients are inoperable or high risk. Nevertheless, female sex constitutes an unfavorable predictive factor for the outcome of transcatheter interventions for heart diseases. In this study we will evaluate baseline clinical characteristics, echocardiography parameters as well as electrocardiographic changes before and after TAVI. Methods: Consecutive patients who underwent TAVI years were evaluated from an existed database. Baseline characteristics were collected before TAVI while echocardiograms and ECGs were recorded before TAVI and daily for 5 days after the procedure. We separated patients in two groups according to gender. Results: Overall, data from 122 patients (pts) (80.42Ϯ5.6 years, AVA: 0.66Ϯ0.14 cm2) were analyzed. Out of them, 62 (pts) (52.5%) were female and 58 (pts) (47.5%) were male. When we compared both groups for baseline clinical characteristics, we found that women had smaller annulus (22.02Ϯ1.62 vs. 23.98Ϯ2.07, pϽ0.01) and aortic valve area (0.63Ϯ0.14 vs. 0.69Ϯ0.13, pϭ0.012) while AVAi did not differ among two sexes (0.37Ϯ0.07 vs. 0.36Ϯ0.08, pϭ0.61). Women had better baseline LVEF (52.16Ϯ9.37 vs. 47.69Ϯ13.01, pϭ0.03) but higher systolic pressure of pneumonic artery (47.35Ϯ13.96 vs. 37.92Ϯ10.95, pϽ0.01) and in higher percentage (45 pts (36.9%) vs. 25 pts (20.5%), pϽ0.01) comparing to men. Permanent pacemaker implantation was lower to women comparing to men (16 pts (13.6%) vs. 29 pts(24.6%), pϽ0.01). Furthermore, women stayed less at coronary care unit (8.07Ϯ4.46 vs. 8.77Ϯ3.75, pϭ0.026). There was no significant difference for major vascular complications (11 pts(9%) vs. 10 pts (8.2%), pϭ1) and transfused blood units (2.3Ϯ4.11 vs. 2.1Ϯ1.7, pϭ0.14). Similarly, in hospital (4 pts(3.3%) vs. 1 pts (0.8%), pϭ0.37) and 30-day mortality (5 pt (7.9%) vs. 2pt (3.6%), pϭ0.44) was not different.
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Conclusions:
In conclusion, women demonstrated better baseline clinical characteristics except for PASP and lower need for permanent pacemaker implantation. However, they did not differ from men as far as short term mortality is concerned.
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